TAXES ON INCOME	6 Months Ended
Jun. 30, 2017
Income Tax Disclosure [Abstract]
TAXES ON INCOME	TAXES ON INCOME For the three and six months ended June 30, 2017, the effective income tax rate was 32.1% and 32.0%, respectively. Income tax expense and the effective income tax rate for the three and six months ended June 30, 2017 benefited from $13 million and $29 million, respectively of excess tax benefits associated with stock-based compensation arrangements. For the three and six months ended June 30, 2016, the effective income tax rate was 47.7% and 45.0%, respectively. Income tax expense for the three and six months ended June 30, 2016 included $2 million and $4 million, respectively of excess tax benefits associated with stock-based compensation arrangements. For both the three and six months ended June 30, 2016 income tax expense includes $84 million associated with the sale of the Focus Diagnostics products business, consisting of $91 million of current income taxes payable and a deferred tax benefit of $7 million. The income tax expense from the sale of the Focus Diagnostics products business resulted in a combined tax rate of 71.4%, which was significantly in excess of the statutory rate primarily due to a lower tax basis in the assets sold, specifically the goodwill associated with the disposition. A full description regarding the Company's adoption of the ASU that simplified several aspects of the accounting for stock-based compensation award transactions, including the income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows and accounting for forfeitures is contained in Note 2 to the consolidated financial statements in the Company's 2016 Annual Report on Form 10-K.

TAXES ON INCOME

For the three and six months ended June 30, 2017, the effective income tax rate was 32.1% and 32.0%, respectively. Income tax expense and the effective income tax rate for the three and six months ended June 30, 2017 benefited from $13 million and $29 million, respectively of excess tax benefits associated with stock-based compensation arrangements.

For the three and six months ended June 30, 2016, the effective income tax rate was 47.7% and 45.0%, respectively. Income tax expense for the three and six months ended June 30, 2016 included $2 million and $4 million, respectively of excess tax benefits associated with stock-based compensation arrangements. For both the three and six months ended June 30, 2016 income tax expense includes $84 million associated with the sale of the Focus Diagnostics products business, consisting of $91 million of current income taxes payable and a deferred tax benefit of $7 million. The income tax expense from the sale of the Focus Diagnostics products business resulted in a combined tax rate of 71.4%, which was significantly in excess of the statutory rate primarily due to a lower tax basis in the assets sold, specifically the goodwill associated with the disposition.

A full description regarding the Company's adoption of the ASU that simplified several aspects of the accounting for stock-based compensation award transactions, including the income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows and accounting for forfeitures is contained in Note 2 to the consolidated financial statements in the Company's 2016 Annual Report on Form 10-K.